A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Anagrelide (Primary)
- Indications Embolism and thrombosis; Essential thrombocythaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire
- 02 May 2016 Primary endpoints updated due to which trial focus changed from AR to Tu and AR.
- 17 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2013 New trial record